logo
Bill Simmons Proposes Wild Trade That Sends Two Celtics Stars Packing To Escape Second Apron Penalty

Bill Simmons Proposes Wild Trade That Sends Two Celtics Stars Packing To Escape Second Apron Penalty

Yahoo19-05-2025

Bill Simmons has never been one to shy away from bold takes, but his latest trade proposal on The Bill Simmons Podcast might be one of his most radical ideas yet. With the Boston Celtics staring down a historic $500 million payroll and the looming second apron tax penalties, Simmons floated a trade scenario that would shake up two franchises and send two All-Star guards packing.
Proposed Trade Details:
Boston Celtics Receive: Fred VanVleet, Jabari Smith Jr., Tari Eason, 2025 No. 10 Pick
Houston Rockets Receive: Jaylen Brown, Jrue Holiday
The Celtics are coming off a disappointing playoff exit, made worse by Jayson Tatum's devastating Achilles injury, which could keep him out for the entire 2025-26 season.
Advertisement
With their championship window in jeopardy and a potentially record-setting tax bill looming, Boston faces a franchise-defining crossroads. Simmons' trade idea reflects the difficult reality that the Celtics front office is now grappling with.
As constructed, the Celtics have already committed $227.8 million in player salaries for next season, according to Spotrac. That's $73 million above the salary cap, $32 million beyond the first apron, and roughly $20 million past the second apron.
Factor in repeat offender tax penalties, and you're looking at an eye-watering $500 million team cost. And that's with Tatum unlikely to play.
Simmons' logic is blunt but compelling: If the Celtics are not title contenders next season due to Tatum's injury, why pay a historically high tax bill? Trading Brown and Holiday would instantly cut salary, inject youth, and provide future assets.
Advertisement
From Houston's side, the deal would signal a shift to full-on contention. The Rockets already have a treasure trove of young talent and cap flexibility. By acquiring Jaylen Brown, who just earned Finals MVP in 2024, and Jrue Holiday, a two-time champion and elite defender, Houston would leap from a playoff squad to a genuine title threat in the West.
Pairing Brown with Alperen Sengun and Jalen Green or potentially flipping Holiday in another deal gives them a veteran backbone without gutting their future entirely.
Meanwhile, Boston would receive Fred VanVleet, a championship point guard on a more manageable contract; Jabari Smith Jr., a 21-year-old stretch big with upside; Tari Eason, a tough-nosed defender; and the No. 10 pick in the draft to keep their prospect pipeline flowing.
VanVleet replaces Holiday's leadership, while Smith and Eason add youth and length to the Celtics' frontcourt. Crucially, it would also drag Boston below the second apron, allowing Brad Stevens to make other trades this summer without being handcuffed by the NBA's new collective bargaining restrictions.
Advertisement
Of course, this move would mean punting on 2025-26 and possibly ending the Tatum-Brown era. But Simmons' vision is clear: the Celtics regroup financially, retool around Tatum for 2026-27, and stay flexible for the long run.
It's aggressive. It's risky. But with a $500 million bill looming and a superstar sidelined, Bill Simmons might be onto something.
Related: Warriors Might Acquire Derrick White If Celtics Initiate Fire Sale

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wayne Gretzky's Daughter Paulina Turns Heads With Outfit After Panthers-Oilers Game 2
Wayne Gretzky's Daughter Paulina Turns Heads With Outfit After Panthers-Oilers Game 2

Yahoo

time19 minutes ago

  • Yahoo

Wayne Gretzky's Daughter Paulina Turns Heads With Outfit After Panthers-Oilers Game 2

Wayne Gretzky's Daughter Paulina Turns Heads With Outfit After Panthers-Oilers Game 2 originally appeared on Athlon Sports. Wayne Gretzky is considered by many to be the greatest NHLer of all-time. The Hall of Fame forward retired holding 40 regular-season records, 15 playoff records, and six all-star records, and since six of them have been broken and he gained a new one—most regular-season points per game— after Mario Lemieux dropped to second place after his NHL return from 2000 to 20025. Advertisement Gretzky's record most career goals was broken earlier this season by Washington Capitals star Alex Ovechkin, and if that weren't enough heartbreak, the 64-year-old legend had to endure more painful news on Saturday when his daughter Paulina made it known publicly she was rooting against her father's Edmonton Oilers in the Stanley Cup Final. Less than 24 hours after the Florida Panthers' 5-4 overtime win over the Oilers in Game 2, Paulina posted a photo of her outfit as she hit the links. The 36-year-old social media influencer, who's also married to PGA tour star Dustin Johnson, was wearing a blank tank top and matching black shorts with a pair of red, white, and black Nike sneakers and a Panthers hat, which she proudly posted with the caption 'love the red.' Wayne Gretzky's daughter Paulina Gretzky shows off her Florida Panthers-themed outfit on SaturdayInstagram (@paulinagretzky) Paulina and Johnson reside in Palm Beach, Florida — just a 50-minute car ride away from the Panthers' Amerant Bank Arena. The couple are proud Panthers fans and have been seen many times supporting the team at games and wearing Panthers gear. Advertisement Meanwhile, Gretzky, who has been serving as a studio analyst for 'NHL on TNT,' spent the bulk of his Hall of Fame career with the Oilers (1979 to 1988). 'The Great One' scored 583 of his 894 career goals and 1,669 of his 2,857 career points in Edmonton, where he led the league in goals five times and points eight times. Paulina Gretzky with her dad, hockey Hall of Famer, Wayne GretzkyJayne Kamin-Oncea-Imagn Images Gretzky holds first (92), second (87), eighth (73) and 11th (71) place on the NHL's single-season goals list, and he holds nine of the top 11 spots on the single-season points list, including the top four spots (215, 212, 208, 205) — all with the Oilers. Gretzky earned nine of his 18 All-Star games, eight of his nine Hart trophies, seven of his 10 Art Ross trophies, and one of his five Lady Byng awards while playing in Edmonton as well. Related: Vancouver Canucks Hit With Brutal Quinn Hughes News This story was originally reported by Athlon Sports on Jun 8, 2025, where it first appeared.

Mangum leads Rays against the Red Sox after 4-hit game
Mangum leads Rays against the Red Sox after 4-hit game

Associated Press

time40 minutes ago

  • Associated Press

Mangum leads Rays against the Red Sox after 4-hit game

Tampa Bay Rays (36-30, second in the AL East) vs. Boston Red Sox (32-36, fourth in the AL East) Boston; Tuesday, 7:10 p.m. EDT PITCHING PROBABLES: Rays: Ryan Pepiot (3-5, 3.20 ERA, 1.13 WHIP, 64 strikeouts); Red Sox: Lucas Giolito (1-1, 6.42 ERA, 1.63 WHIP, 27 strikeouts) BETMGM SPORTSBOOK LINE: Rays -117, Red Sox -103; over/under is 9 1/2 runs BOTTOM LINE: The Tampa Bay Rays take on the Boston Red Sox after Jake Mangum had four hits on Monday in a 10-8 win over the Red Sox. Boston has a 32-36 record overall and a 17-17 record at home. The Red Sox have a 6-17 record in games decided by one run. Tampa Bay is 36-30 overall and 13-10 on the road. The Rays have the ninth-best team ERA in baseball at 3.54. Tuesday's game is the fifth time these teams meet this season. The season series is tied 2-2. TOP PERFORMERS: Rafael Devers has 14 home runs, 54 walks and 57 RBIs while hitting .280 for the Red Sox. Abraham Toro is 17 for 40 with five doubles, a home run and seven RBIs over the last 10 games. Junior Caminero leads the Rays with 30 extra base hits (15 doubles and 15 home runs). Yandy Diaz is 14 for 40 with three doubles, two home runs and seven RBIs over the past 10 games. LAST 10 GAMES: Red Sox: 5-5, .269 batting average, 5.14 ERA, outscored opponents by three runs Rays: 7-3, .249 batting average, 3.36 ERA, outscored opponents by 20 runs INJURIES: Red Sox: Wilyer Abreu: 10-Day IL (oblique), Josh Winckowski: 60-Day IL (elbow), Nick Burdi: 15-Day IL (knee), Justin Slaten: 15-Day IL (shoulder), Liam Hendriks: 15-Day IL (hip), Alex Bregman: 10-Day IL (quadricep), Triston Casas: 60-Day IL (knee), Masataka Yoshida: 60-Day IL (shoulder), Kutter Crawford: 60-Day IL (knee), Tanner Houck: 15-Day IL (flexor), Chris Murphy: 60-Day IL (elbow), Patrick Sandoval: 60-Day IL (elbow) Rays: Jonny Deluca: 60-Day IL (shoulder), Ha-Seong Kim: 60-Day IL (shoulder), Hunter Bigge: 15-Day IL (lat), Shane McClanahan: 60-Day IL (tricep), Richie Palacios: 10-Day IL (knee), Alex Faedo: 60-Day IL (shoulder), Nathan Lavender: 60-Day IL (elbow) ___ The Associated Press created this story using technology provided by Data Skrive and data from Sportradar.

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria
Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

Yahoo

timean hour ago

  • Yahoo

Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study BOSTON and LAUSANNE, Switzerland, June 10, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces the submission of a Clinical Trial Application (CTA) to Germany's Paul-Ehrlich-Institut (PEI) to initiate a Phase 1/1b study of ALY-301 in healthy volunteers and patients suffering from Cold Urticaria, a subtype of Chronic Inducible Urticaria (CIndU). Cold Urticaria is a chronic skin disease where red, itchy wheals or hives appear after the skin is exposed to cold temperatures. It is a well-established clinical model for mast cell-mediated diseases in general, and chronic spontaneous urticaria in particular. Current and emerging solutions do not address the significant unmet medical needs experienced by patients. In conjunction with limited treatment options, the Urticaria market is projected to reach multiple billions within the next ten years. ALY-301 is the first mast cell-selective c-Kit inhibitor to enter the clinic. It is a cis-targeting bispecific antibody binding c-Kit and CD-203c, allowing selective targeting and depletion of mast cells over other c-Kit positive cells. This differentiated profile of ALY-301 is expected to offer a significantly improved safety profile over conventional c-Kit targeting agents and enable safe, chronic dosing in multiple mast-cell dependent diseases such as Chronic Urticaria. The trial will evaluate the safety and efficacy of ALY-301 at multiple sites across Germany. This CTA submission is the first clinical program to emerge from Alys' Granular platform, which is focused on the precise targeting of mast cell biology through advanced antibody engineering. Professor Brian Kim, Sol and Clara Kest Professor of Dermatology and Vice Chair of Research at Icahn School of Medicine at Mount Sinai and Head of Alys Pharmaceuticals Scientific Advisory Board, said: "ALY-301 offers a truly differentiated approach. It is the only c-Kit antibody designed to target activated mast cells while avoiding off-target effects. Unleashing the proven efficacy of c-Kit inhibition on mast cells, while sparing all other cell-types that have been associated with significant side effects, should result in a transformational drug profile for ALY-301 and could have a revolutionary impact on Chronic Urticaria and several other allergic indications." Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "The concept behind ALY-301, to enable safe and effective chronic dosing of a c-Kit agent through mast-cell selectivity, has been strongly supported across all non-clinical studies. It is very exciting to start the clinical journey today, especially since this first clinical trial will yield clinical outcomes from Urticaria patients." Thibaud Portal, Co-Founder and Chief Operating Officer of Alys Pharmaceuticals, added: "Recently, there has been intense attention to solving Urticaria and other allergic diseases, with keen interest in c-Kit targeting. Data have demonstrated the remarkable potency of the mode of action, but indiscriminate c-Kit targeting has been coupled with chronic safety challenges. ALY-301 is a first-in-class approach that combines the power of c-Kit inhibition with selectivity and safety. With its expected safety margin and broad applicability across multiple diseases, this marks another pivotal moment for Alys in our journey to bring innovative treatments to patients." This study marks the second major clinical milestone for Alys Pharmaceuticals. The Alys pipeline includes a diverse portfolio of assets targeting unmet needs in indications such as atopic dermatitis, chronic spontaneous urticaria, vitiligo, and systemic mastocytosis. The Company remains on track to deliver multiple clinical Proof-of-Concept (POC) readouts by 2027. About Alys PharmaceuticalsAlys Pharmaceuticals, Inc. ("Alys") is a Boston and Lausanne-based cutting edge pure-play immuno-dermatology company. Alys is backed by international investment firm Medicxi with $100M financing. Alys has a world class leadership team that brings together experts across dermatology and advanced scientific fields, including co-founders John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), Lars French (LMU, Munich), Craig Mello (UMass Chan Medical School), Eric Deutsch (Gustave Roussy) and Mark Prausnitz (Georgia Institute of Technology). Alys is led by dermatology specialist, co-founder, and COO Thibaud Portal. Its pipeline includes programs targeting multiple dermatological indications, including atopic dermatitis, vitiligo, chronic urticaria, psoriasis and mastocytosis. The Company entered the clinic in Q1 2025 with the siRNA platform developed by its affiliate Aldena Therapeutics, which offers the potential for long-lasting treatments that could transform the dermatology treatment landscape and is now advancing its mastocyte-selective therapies developed by affiliate Granular Therapeutics. For further information, please visit View original content: SOURCE Alys Pharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store